Nature, Published online: 14 October 2026; doi:10.1038/s41586-026-11176-1
A tetravalent nanobody-based myeloid-selective IL-10 receptor agonist recapitulates IL-10’s potent suppression of monocytes, macrophages and dendritic cells while avoiding stimulation of T cells.General
Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism
Nature News0 views
Source：https://www.nature.com/articles/s41586-026-11176-1
PreviousGlobal conservation area coverage substantially exceeds current estimatesNext<i>Elp1</i> is required for myeloid differentiation and brain repopulation
Related posts
How we halved DNS build delay and cut memory use by 85%
0Cloudflare Blog
Birdbuddy vs. Birdfy: Which Budget Smart Feeder Should You Buy? (2026)
0Wired
2 days till TechCrunch Founder Summit: Boston founders don’t need a Silicon Valley address to build something big
0TechCrunch
Adventurer returns home to Hull after 28-year walk from South America
0Hacker News New
![Vending machine has terms and conditions you must accept before using [video]](/storage/uploads/covers/auto/p165008.svg)
Vending machine has terms and conditions you must accept before using [video]
0Hacker News New
![Tomorrow Corporation Tech Demo [video]](/storage/uploads/covers/auto/p165007.svg)
Tomorrow Corporation Tech Demo [video]
0Hacker News New